A Longer Course of Varenicline Therapy Improves Smoking Cessation Rates
Abstract
Smoking exerts strong dose‐dependent increases in cardiovascular risk and mortality, and quitting can profoundly decrease these risks. Varenicline attenuates nicotine addiction by reducing withdrawal symptoms and cravings. A meta‐analysis performed addressed whether a longer duration of varenicline is associated with better abstinence rates than shorter courses of treatment. For this meta‐analysis, a literature search was performed to identify randomized controlled trials investigating the efficacy of the smoking cessation agent varenicline. The association between abstinence and duration of treatment was analyzed using fixed‐effect meta‐regression. Five randomized controlled trials were identified and included in this meta‐analysis. A highly significant relationship (P<.001) was found between the length of exposure to varenicline and abstinence rate. Cessation rates were approximately twice as high with varenicline treatment of 24 weeks compared to 6 weeks. In conclusion, a meta‐analysis of randomized controlled trials suggests that longer duration of varenicline therapy improves long‐term abstinence rates.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Prolonged varenicline treatment significantly decreases relapse rates during the period of administration.
“prolonged varenicline treatment has been shown to significantly decrease relapse rates during the period of administration (Lee et al, 2008)”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Lee et al, 2008
Cites
Jorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635 · see citing works
Shape of the relapse curve and long-term abstinence among untreated smokers
Hughes, J. R., Keely, J., & Naud, S. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00540.x · Cited by 1,414 · see citing works
Panel, S. T. T. U. A. D. C. P. G. (2000) · JAMA · doi:10.1001/jama.283.24.3244 · Cited by 827 · see citing works
Nicotine Activation of α4* Receptors: Sufficient for Reward, Tolerance, and Sensitization
Tapper, A. R., McKinney, S. L., Nashmi, R., Schwarz, J., Deshpande, P., Labarca, C., Whiteaker, P., Marks, M. J., Collins, A. C., & Lester, H. A. (2004) · Science · doi:10.1126/science.1099420 · Cited by 686 · see citing works
Tonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660 · see citing works
Nides, M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1561 · Cited by 390 · see citing works
Nortriptyline and Cognitive-Behavioral Therapy in the Treatment of Cigarette Smoking
Hall, S. M., Reus, V. I., Muñoz, R. F., Sees, K. L., Humfleet, G., Hartz, D. T., Frederick, S., & Triffleman, E. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.8.683 · Cited by 385 · see citing works
Oncken, C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1571 · Cited by 380 · see citing works
Smoking vs Other Risk Factors as the Cause of Smoking-Attributable Deaths
Thun, M. J., Apicella, L. F., & Henley, S. J. (2000) · JAMA · doi:10.1001/jama.284.6.706 · Cited by 307 · see citing works
Godtfredsen, N. S. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf150 · Cited by 199 · see citing works
A double-blind study evaluating the long-term safety of varenicline for smoking cessation
Williams, K. E., Reeves, K. R., Billing, C. B., Pennington, A. M., & Gong, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182185 · Cited by 184 · see citing works
Holm, K. J., & Spencer, C. M. (2000) · Drugs · doi:10.2165/00003495-200059040-00019 · Cited by 175 · see citing works
Foulds, J. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00955.x · Cited by 136 · see citing works
Smoking and Deaths between 40 and 70 Years of Age in Women and Men
Vollset, S. E., Tverdal, A., & Gjessing, H. K. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-6-200603210-00004 · Cited by 129 · see citing works
Qiao, Q. (2000) · European Heart Journal · doi:10.1053/euhj.2000.2151 · Cited by 93 · see citing works
A meta-analysis of double-blind placebo-controlled trials of clonidine for smoking cessation.
Covey, L., & Glassman, A. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01860.x · Cited by 90 · see citing works
Smoking‐Related Morbidity and Mortality in the Cardiovascular Setting
White, W. B. (2007) · Preventive Cardiology · doi:10.1111/j.1520-037x.2007.06050.x · Cited by 58 · see citing works
Nicotine and Non-nicotine Smoking Cessation Pharmacotherapies
Frishman, W. H., Mitta, W., Kupersmith, A., & Ky, T. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000172309.06270.25 · Cited by 49 · see citing works
A Clinical Imperative: Assisting Patients Who Smoke to Reduce Their Risk of Cardiovascular Disease
Bullen, C., Whittaker, R., McRobbie, H. J., & Fagerström, K. O. (2007) · Preventive Cardiology · doi:10.1111/j.1520-037x.2007.06525.x · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747 · see citing works
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433 · see citing works
Relapse prevention interventions for smoking cessation
Livingstone-Banks, J., Norris, E., Hartmann-Boyce, J., West, R., Jarvis, M., Chubb, E., & Hajek, P. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003999.pub6 · Cited by 77 · see citing works
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub4 · Cited by 46 · see citing works
Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal
Turner, J. R., Wilkinson, D. S., Poole, R. L., Gould, T. J., Carlson, G. C., & Blendy, J. A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.105 · Cited by 29 · see citing works
- Authors
- Lee, J. H., Jones, P. G., Bybee, K., & O’Keefe, J. H.
- Affiliations
- University of Missouri–Kansas City (US)
- Corresponding author
- O’Keefe, James H.
- Venue
- Preventive Cardiology
- Publisher
- Wiley
- Published
- 2008-09
- Volume
- 11
- Issue
- 4
- Pages
- 210-214
- ISSN
- 1520-037X (ISSN-L)
- 1751-7141
- OpenAlex
- W2001751389
- Cited by
- 34
- References
- 20
- Citations by year
- 2025: 1 · 2023: 5 · 2022: 1 · 2019: 5 · 2017: 1 · 2016: 3 · 2015: 3 · 2014: 2 · 2013: 3 · 2012: 1
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Preventive Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Keywords
- varenicline, smoking cessation, treatment duration, abstinence rates, nicotine dependence, nicotine withdrawal symptoms, nicotine craving, cardiovascular risk reduction
- MeSH terms
- Varenicline, Smoking Prevention, Benzazepines, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Patient Compliance, Quinoxalines, Receptors, Nicotinic, Randomized Controlled Trials as Topic, Smoking Cessation, Treatment Outcome, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Risk Assessment, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review